UROWebinar: NMIBC – BCG Unresponsive management in 2025 and new developments

NMIBC – BCG Unresponsive management in 2025 and new developments

This recording will focus on Bacillus Calmette-Guérin–unresponsive (BCG-U) non-muscle-invasive bladder cancer (NMIBC). BCG-U NMIBC remains to be a therapeutic challenge due to its substantial risk of progression to muscle-invasive bladder cancer (MIBC), and requires further management including radical cystectomy (RC). In this context, different intravesical and systemic therapies (immunotherapies, gene therapies and drug-delivery devices) emerge as promising alternatives to delay or potentially avoid RC.

In this recording, we will discuss a clinical case of a patient with high-grade BCG-U NMIBC, and examine the different therapeutic options including intravesical and systemic therapies. We will also analyse the efficacy data, as well as the benefit-risk balance including risk of progression and adverse events.

Speakers:
Prof. Dr. E.N. Xylinas (FR)
Dr. G. Marcq (FR)
Prof. S. Shariat (AT)
Dr. F. Soria (IT)

This recording is brought to you in collaboration with the EAU Section of Oncological Urology.

Acknowledgment
This activity is supported by an educational grant from our industry partner - Ferring Pharmaceuticals, with no involvement in the programme or speaker selection.
https://ferringusa.com/

🌟 Important info: The recording of this webinar is not EU-ACME accredited. Missed the live session? Earn 1 CME point by completing our online e-course at: https://uroweb.org/education-events/e.... Don't miss this opportunity! 🎓💡